Methods Serum levels of E2, NT proCNP, insulin like growth factor 1(IGF1), NMID Osteocalcin(OC) and carboxy-terminal cross-linking telopeptide of type I collagen (b-CrossLaps) were measured in healthy 57 girls at different pubertal stages, and in 13 girls with ICPP at the beginning and the end of 6 month and 12 month of GnRHa treatment. Height velocities of the 13 ICPP girls in each 6 months be...

There is a challenging debate on the effect of premature luteinization on the clinical outcome of ‘controlled ovarian hyperstimulation’ (COH) using long ‘gonadotropin–releasing hormone agonist’ (GnRHa) cycles. Premature luteinization is defined as late follicular progesterone/estradiol ratio more than 1 on the day of human chorionic gonadotropin (HCG) administration. We carried out a retrospect...

We present the first Asian case of a 77-year-old man who developed pituitary apoplexy (PA) soon after gonadotropin-releasing hormone agonist (GnRHa) (leuprorelin) injection to treat prostate cancer. Headache, ophthalmoplegia, visual field deficit, nausea, and vomiting are the typical characteristics of pituitary apoplexy. Though the occurrence rate is rare, the consequence of this condition can...

Ž . In three separate experiments, non-spermiating male Atlantic salmon Salmo salar were Ž . injected with a commercial salmon gonadotropin releasing hormone analog GnRHa preparation Ž . or vehicle propylene glycol . After 6 days, fish were also injected with 17a-hydroxyprogesterone Ž . Ž . 17P , 17a ,20b-dihydroxy-4-pregnen-3-one 17,20bP or vehicle. Injections were repeated on day 7, and after...

As many chemotherapy regimens induce follicular depletion, fertility preservation became a major concern in young cancer patients. By maintaining follicles at the resting stage, gonadotropin-releasing hormone analogues (GnRHa) were proposed as an ovarian-protective option during chemotherapy. However, their efficacy and mechanisms of action remain to be elucidated. Mice were dosed with cyclopho...

Abstract Study question Is patients’ BMI associated with oocyte yield and maturation following different trigger strategies r-hCG, GnRH agonist (GnRHa) or dual trigger? Summary answer Patients’ is not triggering rhCG, GnRHa trigger. What known already Triggering final a key step of ovarian stimulation for IVF/ICSI treatment. Although hCG has traditionally been the gold standard maturation, incr...

Gonadotropin-releasing hormone (GnRH) receptor is present in 80% of ovarian cancer, and numerous studies have provided evidence for a role of GnRH in cell proliferation. In this study, the effect of GnRH on the invasion potential of ovarian cancer cells was investigated. In vitro migration and cell invasion assays with the ovarian cancer cell lines Caov-3 and OVCAR-3 revealed the biphasic natur...

OBJECTIVE Ovarian hyperstimulation syndrome (OHSS) is a serious iatrogenic condition, predominantly related to the hormone used to induce oocyte maturation during IVF treatment. Kisspeptin is a hypothalamic neuropeptide that has recently been demonstrated to safely trigger final oocyte maturation during IVF treatment even in women at high risk of OHSS. However, to date, the safety of kisspeptin...

  Purpose: To assess whether bromocriptine-rebound method (BRM) can improve pregnancy   outcomes compared to long protocol after intracytoplasmic sperm injection cycles (ICSIs).   Materials and Methods: A total of 114 women underwent ICSI. Pregnancy outcomes and   hormonal data were compared between two groups, i.e. long protocol and BRM. Ovulatory   women with normal serum prolactin levels wer...